Physician profile
Herbert A King
NPI 1568414092
$11,631.96
in general payments reported to CMS, 2019-2025
58 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $1,306 · 2021: $2,030 · 2022: $1,638 · 2023: $1,683 · 2024: $2,199 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,653.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,124.67 | 2020-2025 | |
| Amgen INC. | $1,081.71 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $1,015.20 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $976.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $631.55 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $605.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.24 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $378.08 | 2019-2025 | Trintellix |
| Allergan, INC. | $350.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $305.46 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.75 | 2020-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $238.97 | 2019-2025 | Capvaxive, Gardasil 9 |
| Abbott Laboratories | $192.37 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $168.44 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $157.67 | 2019-2023 | Xarelto |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.